– Yuyu Pharma reveals the results of studies on the mechanism of action and comparative studies of its peptide for the treatment of dry eye.
SEOUL, South Korea, April 27, 2023 /PRNewswire/ — At ARVO 2023, Yuyu Pharma announced the results of its mechanism of action and head-to-head studies of its dry eye treatment peptide (name of the project: YP-P10). ARVO is the world’s largest ophthalmic society and held its annual meeting in New Orleans, Louisiana, USA in April this year.
A study led by Dr. Virginia Calder, from University College London (UCL), found that YP-P10 significantly reduced Th2 and Th17 inflammatory cells. Specifically, the YP-P10 model reduced Th17 cells 25% more effectively compared to the control group.
The YP-P10 head-to-head preclinical study, jointly conducted by five people, including Dr. Kyungho Park of Naason Science, showed a statistically significant reduction in corneal damage by measuring corneal fluorescein staining (CFS). The study compared the efficacy of YP-P10 with that of several competing products for the treatment of dry eye, including Lifitegrast, cyclosporine, Diquafosol and hyaluronic acid. The results showed that YP-P10 was 12% more effective than Lifitegrast, 7% more effective than cyclosporine, 9% more effective than hyaluronic acid, and similar in efficacy to Diquafosol.
Yuyu Pharma’s Director of Business Development, Laxmikant Neil Gharat, stated: “Through this presentation at ARVO, global ophthalmologists and pharmaceutical companies have once again confirmed their interest in YP-P10. We plan to announce the results of the trial. Phase 2 clinical trial of YP-P10 in the first half of this year”.
Yuyu Pharma anticipates that YP-P10 will be an effective treatment and has completed patent registration in 4 countries (USA, Korea, Australia, Russia) with pending patent applications in 11 other countries.
About YP-P10 Ophthalmic Solution
YP-P10 is a new patented synthetic peptide with anti-inflammatory properties that is being studied for the potential treatment of dry eye disease (DED). In April 2022, Yuyu received authorization from the Food
About Yuyu Pharma
With more than 80 years in the healthcare industry, Yuyu Pharma (KRX: 000220) is a fast-growing global pharmaceutical company founded in Seoul, South Korea. Yuyu is committed to developing innovative therapies in the areas of neurology, dermatology, urology, and ophthalmology. For more information on Yuyu Pharma and YP-P10, please visit YuyupharmaUS.com.
Media contact: Sean Yoon, hjyoon@yuyu.co.kr
Photo – https://mma.prnewswire.com/media/2064512…
View original content: https://www.prnewswire.com/news-releases/yuyu-pharma-desvela-los-resultados-de-los-estudios-sobre-el-mecanismo-de-accion-301809193.html
